诺思格（北京）医药科技股份有限公司 独立董事关于第四届董事会第十二次会议相关议案的独立意见 三、关于选举公司独立董事候选人的议案的独立意见 经核查，我们认为公司董事会提供的独立董事候选人兰立鹏先生的相关资 料，符合《公司法》《上市公司独立董事规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》规定的独立董事任职要求，最近 三十六个月内未受到中国证监会的行政处罚，不存在被中国证监会确定为市场禁 入者并且禁入尚未解除的情形，独立董事的任职资格不违背相关法律、法规、规 范性文件和《公司章程》的禁止性规定。截至目前，独立董事候选人兰立鹏先生 暂未取得独立董事资格证书，已书面承诺参加最近一次独立董事培训并取得深圳 证券交易所认可的独立董事资格证书，符合相关规定。 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第四届董事会 第十二次会议于 2023 年 08 月 09 日召开（以下简称"本次董事会"）。作为公 司的独立董事，根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《上市公司独立董事规则》等 ...

证券简称：诺思格 证券代码：301333 诺思格（北京）医药科技股份有限公司 2023 年限制性股票激励计划 （草案）摘要 2023 年 8 月 诺思格（北京）医药科技股份有限公司 2023 年限制性股票激励计划（草案）摘要 声 明 三、本激励计划拟向激励对象授予的限制性股票数量为 240.00 万股，约占 本激励计划草案公告时公司股本总额 9,600.00 万股的 2.50%。其中首次授予限制 性股票 201.60 万股，约占本激励计划草案公告时公司股本总额 9,600.00 万股的 2.10%，占拟授予权益总额的 84.00%；预留授予 38.40 万股，约占本激励计划草 案公告时公司股本总额 9,600.00 万股的 0.40%，占拟授予权益总额的 16.00%。 截至本激励计划草案公告日，公司全部在有效期内的股权激励计划所涉及的 标的股票总数累计未超过公司股本总额的 20%。本激励计划中任何一名激励对 象通过全部在有效期内的股权激励计划获授的公司股票数量累计未超过公司股 本总额的 1%。 四、本激励计划授予激励对象限制性股票的授予价格为 26.31 元/股。在本激 励计划草案公告当日至激励对象获授的限 ...

证券代码：301333 证券简称：诺思格 公告编号：2023-022 诺思格（北京）医药科技股份有限公司 独立董事候选人声明 声明人兰立鹏 作为诺思格（北京）医药科技股份有限公司第四届董事会独 立董事候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独 立性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券 交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明如下： 一、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 二、本人符合中国证监会《上市公司独立董事规则》规定的独立董事任职 资格和条件。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、本人符合该公司章程规定的独立董事任职条件。 ☑ 是 □ 否 如否，请详细说明：______________________________ 四、被提名人已经参加培训并取得证券交易所认可的相关证书。 □ 是 ☑ 否 如否，请详细说明：_目前尚未取得上市公司独立 ...

第二章 董事会的组成和下设机构 第四条 公司董事会由 9 名董事组成，其中独立董事 3 名。董事会设董事长 1 人。董事长由董事会以全体董事的过半数选举产生。 第五条 董事会设立审计委员会、提名委员会、薪酬与考核委员会和战略委员 会四个专门委员会，也可根据需要设立其他专门委员会。 诺思格（北京）医药科技股份有限公司 董事会议事规则 第一章 一般规定 第一条 诺思格（北京）医药科技股份有限公司（以下简称"公司"）为明确 董事会的职责权限，规范董事会会议及工作程序，确保公司董事会及董事忠实履行 职责，维护公司及股东利益，根据《中华人民共和国公司法》（以下简称《公司法》） 等有关规定以及《诺思格（北京）医药科技股份有限公司章程》（以下简称《公司章 程》）的规定，制定本议事规则。 第二条 公司董事会对股东大会负责。 第三条 董事会下设董事会办公室，负责公司股东大会和董事会会议的筹备、 文件保管以及公司股东资料管理等董事会日常工作。 董事会秘书兼任董事会办公室负责人，保管董事会印章。 专门委员会对董事会负责，依照《公司章程》和董事会授权履行职责，提案应 当提交董事会审议决定。专门委员会成员全部由董事组成，其中审计委员会 ...

创业板上市公司股权激励计划自查表 | | （8）公司授予权益及激励对象行使权益的程序；当中，应当明 | | | --- | --- | --- | | | 确上市公司不得授出限制性股票以及激励对象不得行使权益的 | 是 | | | 期间 | | | | （9）股权激励计划所涉及的权益数量、行权价格的调整方法和 | 是 | | | 程序（例如实施利润分配、配股等方案时的调整方法） | | | | （10）股权激励会计处理方法，限制性股票或者股票期权公允价 | | | | 值的确定方法，估值模型重要参数取值及其合理性，实施股权激 | 是 | | | 励应当计提费用及对上市公司经营业绩的影响 | | | | （11）股权激励计划的变更、终止 | 是 | | | （12）公司发生控制权变更、合并、分立、激励对象发生职务变 | 是 | | | 更、离职、死亡等事项时如何实施股权激励计划 | | | | （13）公司与激励对象各自的权利义务，相关纠纷或者争端解决 机制 | 是 | | | （14）上市公司有关股权激励计划相关信息披露文件不存在虚 | | | | 假记载、误导性陈述或者重大遗漏的承诺；激励对象有关披露文 件 ...

诺思格（北京）医药科技股份有限公司 2023年限制性股票激励计划实施考核管理办法 诺思格（北京）医药科技股份有限公司（以下简称"公司"）为推进公司稳健 发展，进一步建立健全公司长效激励机制，吸引和留住优秀人才，充分调动公司高 级管理人员、中层管理人员、核心技术/业务人员积极性，有效将股东利益、公司 利益和核心团队个人利益结合在一起，增强公司整体凝聚力，使各方共同关注公司 的长远发展，确保公司发展战略和经营目标的实现，公司拟实施2023年限制性股票 激励计划（以下简称"股权激励计划"或"限制性股票激励计划"）。 为保证股权激励计划的顺利实施，现根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则 （2023年修订）》《深圳证券交易所创业板上市公司自律监管指南第1号——业务 办理（2023年2月修订）》等有关法律法规、规范性文件和《公司章程》《诺思格（ 北京）医药科技股份有限公司2023年限制性股票激励计划（草案）》的有关规定， 并结合公司的实际情况，特制定公司《2023年限制性股票激励计划实施考核管理办 法》（以下简称"本办法"）。 一、考核目的 ...

关于诺思格（北京）医药科技股份有限公司 2023 年限制性股票激励计划的法律意见书 致：诺思格（北京）医药科技股份有限公司 北京市君合律师事务所（以下简称"本所"）受诺思格（北京）医药科技 股份有限公司（以下简称"诺思格"、"公司"）的委托，担任诺思格2023年限 制性股票激励计划（以下简称"本次激励计划"）的专项法律顾问，依据《中华 人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以 下简称《证券法》）、《上市公司股权激励管理办法》（以下简称《管理办法》）、 《深圳证券交易所创业板股票上市规则（2023年修订）》（以下简称《上市规则》）、 《深圳证券交易所创业板上市公司业务办理指南第1号——业务办理（2023年2 月修订）》（以下简称《业务办理指南》）及中华人民共和国（包括香港特别行 政区、澳门特别行政区和台湾地区，仅为本法律意见书之目的，特指中国大陆地 区，以下简称"中国"）其他相关法律、法规及规范性文件的有关规定，和《诺 思格（北京）医药科技股份有限公司章程》（以下简称《公司章程》）就本次激 励计划出具本法律意见书。 为出具本法律意见书，本所律师就本次激励计划涉及的相关事实情况，包括 ...

证券代码：301333 证券简称：诺思格 诺思格（北京）医药科技股份有限公司 投资者关系活动记录表 编号：2023-005 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （） 信达证券 金鹰基金 农银人寿 泰致资产 泰达宏利 中金基金 参与单位名称及 中加基金 人员姓名 时间 2023 年 05 月 10 日 地点 北京金融街丽思卡尔顿酒店 董事、副总经理：滕乐燕 上市公司接待人 证券事务代表：齐士坤 员姓名 1、国内医药研发、临床 CRO 外包宏观环境的变化情况？ 从去年三季度开始，我们观察到国内的临床试验需求端是 在一个逐步恢复的过程中，我们也逐渐的收到了更多的客户询 价和竞标的方面的需求，但同时在临床运营服务、数统服务以及 临床试验现场管理服务等多个业务版块的竞争也变得比较激 烈。 2、公司关于国际化的规划和部署情况？ 投资者关系活动 我们认为，海外临床药物研发的市场非常广阔，机遇也非常 多，这也是一家临床 CRO 公司想要发展壮大，必然要走的一个 主要内容介绍 方向。我们的国际化布局起步于美国子公司的设立，公司近几年 境外收 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.47% compared to ¥170,242,153.31 in the same period last year[5] - Net profit attributable to shareholders was ¥28,792,801.97, representing an increase of 7.63% from ¥26,751,469.21 year-on-year[5] - The basic and diluted earnings per share decreased by 18.64%, from ¥0.59 to ¥0.48[5] - Total operating revenue for Q1 2023 was CNY 160,932,583.88, a decrease of 5.7% compared to CNY 170,242,153.31 in Q1 2022[24] - Net profit for Q1 2023 reached CNY 28,678,469.89, an increase of 5.0% from CNY 27,307,384.49 in Q1 2022[26] - The total comprehensive income for the first quarter of 2023 was CNY 28,776,416.25, compared to CNY 27,327,655.65 in the same period last year, representing an increase of approximately 5.3%[27] Cash Flow and Liquidity - The net cash flow from operating activities surged by 324.03%, reaching ¥17,791,127.98 compared to ¥4,195,764.85 in the previous year[14] - The cash and cash equivalents net increase was -¥203,432,426.29, a 229.38% increase in outflow compared to -¥61,761,996.01 in the previous year[14] - The company's cash and cash equivalents decreased to ¥1,318,869,376.19 from ¥1,522,301,802.48 at the beginning of the year, representing a decline of approximately 13.4%[21] - Cash inflow from investment activities totaled CNY 960,758,579.90, a substantial rise from CNY 183,873,392.38 year-over-year[30] - The net cash flow from investment activities was negative CNY 217,277,058.98, compared to negative CNY 17,572,346.41 in the same period last year, indicating a worsening position[30] - The total cash outflow from financing activities was CNY 2,884,230.04, compared to CNY 48,125,141.86 in the previous year, showing a significant reduction of about 94.0%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,922,065,259.29, reflecting a 2.19% increase from ¥1,880,941,437.34 at the end of the previous year[5] - Total liabilities increased to CNY 299,243,667.60 in Q1 2023, compared to CNY 286,982,213.23 in Q1 2022, representing a rise of 4.4%[23] - The company's total assets as of Q1 2023 amounted to CNY 1,922,065,259.29, up from CNY 1,880,941,437.34 at the end of Q1 2022, indicating a growth of 2.2%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,657[15] - The number of shares held by the top 10 unrestricted shareholders includes significant stakes from entities such as the Macau Financial Management Bureau and Kuwait Investment Authority, with holdings of ¥853,506 and ¥849,312 respectively[18] - The company has established consistent action agreements among major shareholders to maintain alignment on significant corporate matters[18] Government Support and Other Income - The company received government subsidies amounting to ¥3,874,649.00, which contributed to the increase in other income by 470.83%[12] Research and Development - Research and development expenses for Q1 2023 were CNY 13,570,366.43, up from CNY 12,565,071.46 in Q1 2022, reflecting an increase of 8.0%[24] Financial Management - The company reported a significant increase in financial income, with investment income rising by 559.33% to ¥5,758,579.90 from ¥873,392.38 in the previous year[12] - The company's weighted average return on equity decreased to 1.80% from 6.14% in the previous year, a decline of 4.34%[5] - The company reported a decrease in financial expenses, with a net financial cost of CNY -1,081,831.83 in Q1 2023, compared to CNY 219,257.85 in Q1 2022[26] Operational Metrics - Operating costs for Q1 2023 were CNY 102,313,022.59, down from CNY 105,791,748.21 in the same period last year, reflecting a cost reduction of approximately 4.4%[24] - The company reported a cash inflow of CNY 153,077,038.71 from sales of goods and services, an increase from CNY 136,263,341.28 in the same quarter last year, representing an increase of approximately 12.7%[29] - The total cash outflow from operating activities was CNY 141,395,795.77, compared to CNY 132,650,901.64 in the previous year, indicating an increase of about 6.0%[30] Future Outlook - The company has not provided specific future guidance or performance outlook in this quarter's report[19] - The company has not disclosed any new product developments or technological advancements in this quarter[19] - There are no updates on market expansion or mergers and acquisitions in the current report[19] - The report indicates no changes in restricted shares during the quarter[19] Audit Information - The company did not conduct an audit for the first quarter report[31]

Financial Performance - The company's operating revenue for 2022 was ¥637,520,243.17, representing a 4.78% increase from ¥608,425,821.40 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥113,592,222.90, a 14.47% increase compared to ¥99,237,035.17 in 2021[21]. - The net cash flow from operating activities for 2022 was ¥130,465,983.24, up 13.87% from ¥114,573,627.51 in 2021[21]. - The total assets at the end of 2022 amounted to ¥1,880,941,437.34, a significant increase of 177.64% from ¥677,471,603.55 at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were ¥1,587,985,580.78, reflecting a 275.83% increase from ¥422,531,037.54 at the end of 2021[21]. - The basic earnings per share for 2022 were ¥2.22, slightly up by 0.45% from ¥2.21 in 2021[21]. - The diluted earnings per share for 2022 were also ¥2.22, maintaining the same increase of 0.45% from ¥2.21 in 2021[21]. - The company reported a weighted average return on equity of 12.54% for 2022, down from 26.63% in 2021, indicating a decrease of 14.09%[21]. - The quarterly operating revenue for Q4 2022 was ¥169,334,232.02, showing a recovery from the previous quarters[23]. - The net profit attributable to shareholders in Q4 2022 was ¥29,747,636.27, indicating a positive trend in profitability towards the end of the year[23]. Dividend and Capital Reserves - The company plans to distribute a cash dividend of 2.50 RMB per 10 shares to all shareholders, based on a total of 60,000,000 shares[3]. - The company will also increase capital reserves by converting 6 shares for every 10 shares held by shareholders[3]. Risk Management and Compliance - The management discussed potential risks and countermeasures in the section on future development outlook[3]. - The report outlines the company's commitment to transparency and legal responsibility for the information provided[3]. - The company emphasizes the importance of risk awareness for investors regarding future plans and forecasts[3]. - The financial report has been confirmed as true, accurate, and complete by the company's responsible persons[3]. - The report is prepared in accordance with the relevant financial reporting standards and regulations[3]. Research and Development - The company has established a comprehensive R&D service system since its inception in 2008, focusing on clinical trial outsourcing services[34]. - The company aims to enhance its service capabilities in response to the rising internationalization of drug development and regulatory standards[33]. - The company emphasizes the importance of early identification of product viability and effective R&D strategies to meet market needs[32]. - The company has a strong focus on quality management and regulatory knowledge to assist clients in navigating complex industry environments[34]. - R&D expenses increased by 21.37% to ¥49,993,012.97, reflecting the company's commitment to innovation[60]. - The total R&D investment for 2022 was approximately ¥49.99 million, representing 7.84% of total revenue, an increase from 6.77% in 2021[62]. - The number of R&D personnel increased to 250 in 2022, up 16.28% from 215 in 2021, with a higher proportion of staff under 30 years old[62]. Market Expansion and Strategy - The company plans to undertake more international multi-center clinical research projects to compete directly with international CRO companies[87]. - The company is actively expanding its global footprint and innovating clinical trial technologies to meet international regulatory trends[51]. - The company focuses on providing comprehensive CRO services to global pharmaceutical enterprises, aiming to improve drug development success rates and reduce R&D risks[50]. - The company has ongoing projects focused on AI-assisted clinical trial design, aiming to enhance operational efficiency and attract early clients[60]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotech sector[119]. - Market expansion efforts include entering two new international markets, aiming for a 15% increase in market share by the end of 2023[118]. Corporate Governance - All board members attended the meeting to review the annual report[3]. - The board of directors consists of 9 members, including 3 independent directors, and held 8 meetings during the reporting period, adhering to legal and regulatory requirements[98]. - The supervisory board has 3 members, including 1 employee supervisor, and convened 6 meetings, all in compliance with legal and regulatory standards[99]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring no financial resources are misappropriated[104]. - The company has a governance structure that does not involve differential voting rights arrangements[112]. - The company is committed to maintaining the interests of minority shareholders and ensuring effective governance practices[137]. Employee Management - The company has established a complete and fair compensation management system to align employee interests with company performance, enhancing employee motivation[143]. - The company has implemented a training program to improve employee skills and efficiency, focusing on new employee orientation and ongoing education[144]. - The total number of employees at the end of the reporting period was 1,926, with 1,789 being technical personnel, representing approximately 92.9% of the workforce[142]. - The company has a total of 267 employees with a master's degree or higher, accounting for approximately 13.9% of the workforce[142]. Environmental and Social Responsibility - There were no reported environmental penalties or issues during the reporting period, indicating compliance with environmental regulations[158]. - The company aims to enhance its corporate culture, promoting values such as inclusivity, harmony, and professionalism[157]. - The company has not reported any significant actions regarding poverty alleviation or rural revitalization initiatives[163]. Future Outlook - Future outlook suggests a projected revenue growth of approximately 20% for 2023, driven by new product launches and market expansion strategies[116]. - The company is actively investing in R&D for new technologies, with a budget allocation of 5 million for the development of innovative pharmaceutical solutions[117]. - A new product line is expected to launch in Q3 2023, anticipated to contribute an additional 10% to overall revenue[120]. - The management team has undergone changes, with new appointments aimed at strengthening operational efficiency and strategic direction[121]. Shareholder Relations - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing[165]. - The company will not repurchase any shares that were issued prior to the public offering during the lock-up period[167]. - The company has fulfilled all commitments related to shareholding and lock-up periods as of the reporting date[165]. - The company reported a commitment to reduce shareholding after the lock-up period, with a maximum of 25% of shares held before the IPO to be sold within two years[174].